Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLF7SG)

• Drug Name: [3H]AMPA Drug Info
• Synonyms: alpha-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ampa; 74341-63-2; 77521-29-0; (RS)-AMPA; AMPA (pharmaceutical); CHEMBL13378; CHEBI:34018; 4-Isoxazolepropanoic acid, alpha-amino-2,3-dihydro-5-methyl-3-oxo-; gamma-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; dl-alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; (+-)-alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; D,L-alpha-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid; AMPA
• Cross-matching ID:
  PubChem CID: 1221
  ChEBI ID: CHEBI:34018
  CAS Number: CAS 77521-29-0
  TTD Drug ID: DMLF7SG

Molecule-Related Drug Atlas

Drug(s) Targeting Glutamate receptor AMPA 1 (GRIA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[5]
NBQX	DMPHZI5	Neurological disorder	6B60	Phase 1	[6]
YM-90K	DMWRT4L	Convulsion	8A68.Z	Discontinued in Phase 2	[7]
Farampator	DM76GRQ	Major depressive disorder	6A70.3	Discontinued in Phase 1	[8]
GYKI-52466	DM3YG5P	Alzheimer disease	8A20	Terminated	[9]
GYKI-53655	DMC0JN8	N. A.	N. A.	Terminated	[10]
Zonampanel	DM70HZD	N. A.	N. A.	Terminated	[7]
SORETOLIDE	DMTDLHG	Convulsion	8A68.Z	Terminated	[11]
[3H]kainate	DMMK7XU	Discovery agent	N.A.	Investigative	[12]
DNQX	DMQXPA5	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting Glutamate receptor AMPA 2 (GRIA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[5]
Paliroden	DMX8ZAQ	Parkinson disease	8A00.0	Phase 2	[14]
[3H]CNQX	DMIFKUX	Discovery agent	N.A.	Investigative	[2]
ATPO	DMXLS78	Discovery agent	N.A.	Investigative	[2]
(S)-5-fluorowillardiine	DMCIZ7P	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Glutamate receptor AMPA 3 (GRIA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[5]
[3H]CNQX	DMIFKUX	Discovery agent	N.A.	Investigative	[3]
ATPO	DMXLS78	Discovery agent	N.A.	Investigative	[3]
(S)-5-fluorowillardiine	DMCIZ7P	Discovery agent	N.A.	Investigative	[3]
joro toxin	DMYBJ4K	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Glutamate receptor AMPA 4 (GRIA4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
E-2007	DMJDYNQ	Diabetic neuropathy	8C0Z	Approved	[5]
[3H]CNQX	DMIFKUX	Discovery agent	N.A.	Investigative	[4]
ATPO	DMXLS78	Discovery agent	N.A.	Investigative	[4]
(S)-5-fluorowillardiine	DMCIZ7P	Discovery agent	N.A.	Investigative	[4]
joro toxin	DMYBJ4K	Discovery agent	N.A.	Investigative	[4]
AMG-889436	DMKP8L9	Parkinson disease	8A00.0	Investigative	[4]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate receptor AMPA 1 (GRIA1)	TTVPQTF	GRIA1_HUMAN	Agonist	[1]
Glutamate receptor AMPA 2 (GRIA2)	TT9HLZ0	GRIA2_HUMAN	Agonist	[2]
Glutamate receptor AMPA 3 (GRIA3)	TT82EZV	GRIA3_HUMAN	Modulator	[3]
Glutamate receptor AMPA 4 (GRIA4)	TTPJR0G	GRIA4_HUMAN	Agonist	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 444).
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 445).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 446).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447).
• [5] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [6] Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
• [7] Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl gr... Bioorg Med Chem Lett. 2004 Oct 18;14(20):5107-11.
• [8] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [9] New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):167-70.
• [10] Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J Med Chem. 1996 Jan 19;39(2):343-6.
• [11] Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;(197):19-24.
• [12] 1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of pot... J Med Chem. 2008 Oct 23;51(20):6614-8.
• [13] Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8.
• [14] Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives.ACS Chem Neurosci.2013 Apr 17;4(4):635-44.